Patents Assigned to Clavis Pharma AS
-
Patent number: 9428540Abstract: The present invention relates to certain unsaturated fatty acid derivatives of therapeutically active glucocorticoides-fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents and pharmaceutical formulations containing them.Type: GrantFiled: March 13, 2008Date of Patent: August 30, 2016Assignee: CLAVIS PHARMA ASAInventors: Finn Myhren, Marit Liland Sandvold, Ole Henrik Eriksen, Steinar Hagen
-
Patent number: 8912162Abstract: The present invention relates to parenteral formulations for certain long chain saturated and monounsaturated fatty acid derivatives of 1-?-D-arabinofuranosylcytosine (cytarabine). In particular, the present invention relates to a parenteral pharmaceutical composition and a method of the preparation thereof, in order to accommodate therapeutically effective doses of the said derivatives ameliorating compliance in treatment of cancer.Type: GrantFiled: July 1, 2011Date of Patent: December 16, 2014Assignee: Clavis Pharma ASAInventors: Sayeh Ahrabi, Finn Myhren, Ole Henrik Eriksen
-
Publication number: 20130196941Abstract: The present invention relates to parenteral formulations for certain long chain saturated and monounsaturated fatty acid derivatives of 1-?-D-arabinofuranosylcytosine (cytarabine). In particular, the present invention relates to a parenteral pharmaceutical composition and a method of the preparation thereof, in order to accommodate therapeutically effective doses of the said derivatives ameliorating compliance in treatment of cancer.Type: ApplicationFiled: July 1, 2011Publication date: August 1, 2013Applicant: CLAVIS PHARMA ASAInventors: Sayeh Ahrabi, Finn Myhren, Ole Henrik Eriksen
-
Patent number: 8399420Abstract: The present invention is directed toward compounds of Formula (I) as follows: wherein, R is H, R5C(O), R5CH2OC(O), or R5CH2NHC(O); R1 is where the crossing dashed line illustrates the bond formed joining R1 to the molecule of Formula (I); R2 and R3 are independently OH or H, provided that R2 and R3 are not simultaneously OH; R4 is H, R5C(O), R5CH2OC(O), or R5CH2NHC(O), provided that R and R4 are not simultaneously H; and R5 has the general formula: CH3—(CH2)n—(CH?CH—CH2)m—CH?CH—(CH2)k—; k is an integer from 0 to 7; m is an integer from 0 to 2; and n is an integer from 0 to 10, or a pharmaceutical salt thereof. Methods of making and using these compounds are also disclosed.Type: GrantFiled: September 25, 2008Date of Patent: March 19, 2013Assignees: Mount Sanai School of Medicine, Clavis Pharma ASAInventors: Lewis Silverman, James Holland, Marit Liland Sandvold, Finn Myhren, Ole Henrik Eriksen
-
Patent number: 8349834Abstract: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives fall within formula (I). Compounds of formula (I) can be used in the treatment of a cancerous disease, including solid tumors and haematological cancers such as leukaemias, lymphomas and multiple myelomas.Type: GrantFiled: December 7, 2006Date of Patent: January 8, 2013Assignee: Clavis Pharma ASInventors: Finn Myhren, Marit Liland Sandvold, Steinar Hagen, Ole Henrik Eriksen
-
Publication number: 20130005678Abstract: This invention provides methods and compositions for treating or otherwise ameliorating cancer in a subject, along with methods and compositions for measuring the levels of nucleoside transporters in a tumor and correlating this level to a predicated efficacy of a given anti-cancer drug regime, and methods and compositions for treating patients with low levels of hENT1 expression in cancer cells using a lipophilic gemcitabine analog such as gemcitabine-5?-elaidate.Type: ApplicationFiled: March 30, 2011Publication date: January 3, 2013Applicant: CLAVIS PHARMA ASAInventors: Marit Liland Sandvold, Finn Myhren
-
Publication number: 20110281815Abstract: The present invention relates to parenteral formulations for certain long chain saturated and monounsaturated fatty acid derivatives of 2?,2?-difluorodeoxycytidine (Gemcitabine). In particular, the present invention relates to a parenteral pharmaceutical composition and a method of the preparation thereof, in order to accommodate therapeutically effective doses of the said derivatives ameliorating compliance in treatment of cancer.Type: ApplicationFiled: November 15, 2010Publication date: November 17, 2011Applicant: CLAVIS PHARMA ASInventors: Sayeh Ahrabi, Finn Myhren, Ole Henrik Eriksen
-
Publication number: 20100099654Abstract: The present invention relates to certain unsaturated fatty acid derivatives of therapeutically active glucocorticoides-fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents and pharmaceutical formulations containing them.Type: ApplicationFiled: March 13, 2008Publication date: April 22, 2010Applicant: CLAVIS PHARMA ASAInventors: Myhren Finn, Marit Liland Sandvold, Ole Henrik Eriksen, Steinar Hagen
-
Publication number: 20100062996Abstract: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula (I)” herein. Compounds of formula (I) can be used in the treatment of a cancerous disease. Treatment of both solid tumours and haematological cancers such as leukaemias, lymphomas and multiple myelomas are included.Type: ApplicationFiled: December 7, 2006Publication date: March 11, 2010Applicant: CLAVIS PHARMA ASInventors: Finn Myhren, Marit Liland Sandvold, Steinar Hagen, Ole Henrik Eriksen
-
Publication number: 20090209477Abstract: The present invention is directed toward compounds of Formula (I) as follows: wherein, R is H, R5C(O), R5CH2OC(O), or R5CH2NHC(O); R1 is where the crossing dashed line illustrates the bond formed joining R1 to the molecule of Formula (I); R2 and R3 are independently OH or H, provided that R2 and R3 are not simultaneously OH; R4 is H, R5C(O), R5CH2OC(O), or R5CH2NHC(O), provided that R and R4 are not simultaneously H; and R5 has the general formula: CH3—(CH2)n—(CH?CH—CH2)m—CH?CH—(CH2)k—; k is an integer from 0 to 7; m is an integer from 0 to 2; and n is an integer from 0 to 10, or a pharmaceutical salt thereof. Methods of making and using these compounds are also disclosed.Type: ApplicationFiled: September 25, 2008Publication date: August 20, 2009Applicants: MOUNT SINAI SCHOOL OF MEDICINE, CLAVIS PHARMA AGInventors: Lewis Silverman, James Holland, Marit Liland Sandvold, Finn Myhren, Ole Henrik Eriksen
-
Publication number: 20080280851Abstract: The present invention relates to oral dosage forms of certain long chain saturated and monounsaturated fatty acid derivatives of 2?,2?-difluorodeoxycytidine (Gemcitabine). In particular, the present invention relates to the use of the said gemcitabine derivatives or a pharmaceutical acceptable salt thereof for preparing an oral dosage form ameliorating compliance in treatment of cancer.Type: ApplicationFiled: March 7, 2006Publication date: November 13, 2008Applicant: Clavis Pharma ASInventors: Finn Myhren, Marit Liland Sandvold, Ole Henrick Eriksen
-
Publication number: 20070225248Abstract: The present invention relates to oral dosage forms of certain long chain saturated and monounsaturated fatty acid derivatives of 2?,2?-difluorodeoxycytidine (Gemcitabine). In particular, the present invention relates to the use of the said gemcitabine derivatives or a pharmaceutical acceptable salt thereof for preparing an oral dosage form ameliorating compliance in treatment of cancer.Type: ApplicationFiled: March 21, 2006Publication date: September 27, 2007Applicant: Clavis Pharma ASInventors: Finn Myhren, Marit Sandvold, Ole Eriksen
-
Publication number: 20070135436Abstract: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula I” herein. Compounds of formula I can be used in the treatment of a cancerous disease. Treatment of both solid tumours and haematological cancers such as leukaemias, lymphomas and multiple myelomas are included.Type: ApplicationFiled: December 19, 2005Publication date: June 14, 2007Applicant: Clavis Pharma ASInventors: Finn Myhren, Marit Sandvold, Steinar Hagen, Ole Eriksen